Relfovetmab

Last updated

Relfovetmab
Monoclonal antibody
Type Whole antibody
Target Nerve growth factor
Clinical data
Other namesZTS-00084768
ATC code
Identifiers
CAS Number
UNII
Chemical and physical data
Formula C6580H10118N1760O2038S46
Molar mass 147964.37 g·mol−1

Relfovetmab is an experimental veterinary medication. It is a felinized monoclonal antibody targeting nerve growth factor. Nerve growth factor binds to TrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself. [1] These inflammatory mediators lead to further peripheral sensitization involved in pain perception. [1] The inhibition of nerve growth factor was demonstrated to provide relief from pain associated with osteoarthritis. [1]

Contents

Society and culture

In September 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Portela, solution for injection, intended for cats. [1] The applicant for this veterinary medicinal product is Zoetis Belgium. [1]

Names

Relfovetmab is the international nonproprietary name. [2]

References

  1. 1 2 3 4 5 "Portela EPAR". European Medicines Agency (EMA). 12 September 2025. Retrieved 28 September 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ↑ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl: 10665/330879 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.